Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Grünenthal GmbH
This trial comprises a total observation period of up to 78 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The participant has given written informed consent to participate.
The participant is 18 years of age or older at the Screening Visit.
The participant has a diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria and functional capacity class of I to III.
There is a documented history indicating that participant has insufficient pain relief with previous Standard of Care.
You may not be if
The participant has past joint replacement surgery of the index knee.
The participant has a history of significant trauma or surgery (e.g., open or arthroscopic) to the index knee within 12 months of Screening.
The participant has periarticular pain at the index knee from any cause other than osteoarthritis, including referred pain, bursitis, tendonitis.
The participant has clinical hip osteoarthritis on the side of the index knee.
The participant has a history of osteonecrosis, subchondral insufficiency fracture, atrophic osteoarthritis, rapidly progressing osteoarthritis (RPOA) Type I or Type II,pathologic fracture, primary or metastatic tumor, or joint infection in the index knee.
The participant has significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the target knee (varus \>10°, valgus \>10°) by radiograph as assessed by independent Central Readers at Screening Visit.
The participant has other conditions that could affect trial endpoint assessments of the index knee.
The participant has current clinically significant disease(s) or condition(s) that may affect safety assessments, or any other reason which may preclude the participant's participation for the full duration of the trial.
The participant has a history of hypersensitivity to resiniferatoxin (RTX) or any similar component (capsaicin, chili peppers).
The participant is currently participating or was participating in another investigational drug trial within 3 months prior to the Screening Visit.
The participant is an employee of the investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial site or is a family member of the employees or the investigator.
Clareo Health | Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
